SCHEMBL6634069

SCHEMBL6634069

NCc1cccc(C(=O)NC(COCc2ccc(F)cc2F)C(=O)N2CCN3C(=O)N(CC(F)(F)F)C(=O)C3(Cc3ccccn3)C2)c1

nearest known ligand 0.54

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 5/20 0.54
UGCG Q16739 13/20 0.39
CYP3A4 P08684 3/20 0.34
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
GPR132 Q9UNW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6634185 0.92 GHSR (0.43) GHSRUGCGCYP3A4GPR132
SCHEMBL6791812 0.92 GHSR (0.43) GHSRUGCGCYP3A4GPR132
SCHEMBL6789921 0.91 GHSR (0.55) GHSRUGCGCYP3A4MEN1KMT2A
SCHEMBL5225202 0.87 GHSR (0.70) GHSRUGCGCYP3A4MEN1KMT2A
SCHEMBL5226022 0.87 GHSR (0.70) GHSRUGCGCYP3A4MEN1KMT2A
SCHEMBL6636084 0.85 GHSR (0.53) GHSRUGCGMEN1KMT2A
SCHEMBL6633523 0.84 GHSR (0.43) GHSRUGCGCYP3A4
SCHEMBL6633620 0.84 GHSR (0.45) GHSRUGCGCYP3A4
SCHEMBL6640209 0.82 GHSR (0.42) GHSRUGCGCYP3A4
SCHEMBL7597562 0.82 GHSR (0.42) GHSRUGCGCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6686359-B2 ANIMAL GROWTH REGULATORS; OSTEOPOROSIS; CONGESTIVE HEART FAILURE; MUSCULAR DISORDERS PFIZER INC. 2004-02-03 US claimed
US-20030130284-A1 Growth hormone secretagogues CARPINO PHILIP A (US) 2003-07-10 US claimed
US-6559150-B2 Neurotransmitter stimulants; antidiabetic agents; congestive heart failure; obesity; frailty; maintaining renal and catabolic homeostasis; bone fracture repair; reducing cachexia and protein loss; muscle strength and burns. PFIZER INC. 2003-05-06 US claimed
US-20020045622-A1 Growth hormone secretagogues CARPINO PHILIP A (US) 2002-04-18 US claimed
EP-0995748-A1 Growth hormone secretagogues Pfizer Products Inc. (US) 2000-04-26 EP claimed
EP-0995748-B1 Growth hormone secretagogues PFIZER PROD INC (US) 2004-03-31 EP disclosed
US-6686359-B2 ANIMAL GROWTH REGULATORS; OSTEOPOROSIS; CONGESTIVE HEART FAILURE; MUSCULAR DISORDERS PFIZER INC. 2004-02-03 US disclosed
US-20030130284-A1 Growth hormone secretagogues CARPINO PHILIP A (US) 2003-07-10 US disclosed
US-6559150-B2 Neurotransmitter stimulants; antidiabetic agents; congestive heart failure; obesity; frailty; maintaining renal and catabolic homeostasis; bone fracture repair; reducing cachexia and protein loss; muscle strength and burns. PFIZER INC. 2003-05-06 US disclosed
US-20020045622-A1 Growth hormone secretagogues CARPINO PHILIP A (US) 2002-04-18 US disclosed
US-6358951-B1 ADMINISTERING PYRAZOLO(4,3-C)PYRIDINE DERIVATIVE TO TREAT OBESITY, CONGESTIVE HEART FAILURE, OSTEOPOROSIS, AGING, BONE AND MUSCULAR DISORDERS PFIZER INC. 2002-03-19 US disclosed
EP-0995748-A1 Growth hormone secretagogues Pfizer Products Inc. (US) 2000-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045622-A1 Growth hormone secretagogues GHSR, GHRHR, GIPR GHSR 1/4885UGCG 1631/4885CYP3A4 3346/4885
US-20030130284-A1 Growth hormone secretagogues GHSR, GHRHR, GIPR GHSR 1/4885UGCG 1631/4885CYP3A4 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.